Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?

• Published in: Tumour virus research Vol. 16; p. 200263
• Main Author: Stern, Peter L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2023; Elsevier
• Subjects: Carcinoma in Situ - complications; Conference report; Female; Human Papillomavirus Viruses; Humans; Immunotherapy; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - therapeutic use; Uterine Cervical Neoplasms - prevention & control
• ISSN: 2666-6790; 2666-6790
• DOI: 10.1016/j.tvr.2023.200263

The International Papillomavirus Conference was held in Washington DC in April 2023 and encompassed wide ranging basic, clinical and public health research relating to animal and human papillomaviruses. This editorial is a personal reflection, it does not attempt to be comprehensive and reports on some key aspects centred on the prospects for immune interventions in prevention and treatment of HPV infections and early precancers with a focus on cervical neoplasia. There is optimism for the future impact of immunotherapy in treating early HPV associated disease. This will depend on developing an appropriate design of vaccines and delivery vehicles which then need to be properly tested in clinical trials that are able to measure a useful clinical endpoint. Thereafter vaccines (prophylactic or therapeutic) still need global access and sufficient uptake to deliver impact and a key and necessary driver is education.